CRISPR Therapeutics

CRISPR Therapeutics is a prominent gene editing firm that uses its unique CRISPR/Cas9 platform to generate transformational gene-based therapies for serious diseases. CRISPR/Cas9 is a revolutionary gene editing technology that enables precise, targeted modifications to genomic DNA. CRISPR Therapeutics is developing a treatment portfolio for a variety of diseases, including hemoglobinopathies, cancer, regenerative medicine, and rare diseases.

CRISPR Therapeutics has formed partnerships with top firms such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. to speed up and expand its operations. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and has a wholly-owned US subsidiary, CRISPR Therapeutics, Inc., with R&D activities in Cambridge, Massachusetts, as well as business offices in San Francisco, California and London, United Kingdom.

Several drugs are being developed by the company. These include CTX001, a drug being developed in collaboration with Vertex Pharmaceuticals for the treatment of the rare blood disorders Beta thalassemia and sickle cell disease. CTX001 was designated as an orphan medicine by the US Food and Medicine Administration in May 2020 for transfusion-dependent beta-thalassemia and by the European Medicines Agency for sickle cell disease and transfusion-dependent beta-thalassemia.

Founded: 2013
Headquarters: Zug, Switzerland
Website: https://crisprtx.com/